OCULAR PHARMACOKINETICS OF LENS EPITHELIAL CELL-SPECIFIC IMMUNOTOXIN 4197X-RA

被引:7
作者
CROSSON, CE
KELLEHER, PJ
LAM, DMK
机构
[1] HOUSTON BIOTECHNOL INC,3608 RES FOREST DR,THE WOODLANDS,TX 77381
[2] BAYLOR COLL MED,CTR BIOTECHNOL,THE WOODLANDS,TX 77381
关键词
IMMUNOTOXIN; PHARMACOKINETICS; OCULAR DISPOSITION; SYSTEMIC DISPOSITION; AQUEOUS FLOW;
D O I
10.1016/0014-4835(92)90096-B
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The ocular clearance, stability and systemic distribution of a lens epithelial cell-specific immunotoxin were evaluated in adult Dutch Belted rabbits. Immunotoxin 4197X-RA was prepared from a murine monoclonal antibody conjugated by a disulfide linkage to ricin A. After intracameral (i.c.) injection, clearance of the immunotoxin from the eye followed a first-order process. The half-life (t 1 2) of immunotoxin in the aqueous humor was 51 min. Accumulation of the immunotoxin in ocular tissues appeared to be associated with aqueous outflow tracts, as it was primarily confined to the iris and the limbal regions of the cornea. No acute metabolism of immunotoxin was observed in the anteior chamber. The immunotoxin was detected in the blood 20 min post-injection and achieved a steady-state level after 40 to 180 min. A slow decline in labeled protein was then observed from 180 min to 24 hr. Systemic clearance of the immunotoxin appeared to occur primarily by way of the kidneys. The present data indicate that immunotoxin 4197X-RA, like other large proteins, is passively cleared from the anterior chamber by aqueous flow, and that little or no acute breakdown occurs in the anterior chamber. It is anticipated that these data, along with results from cytotoxicity studies, will result in the determination of optimal doses and frequency of administration for the use of immunotoxin in human clinical trials. © 1992.
引用
收藏
页码:87 / 91
页数:5
相关论文
共 16 条
[1]  
Brubaker R.F., 1989, GLAUCOMAS, P337
[2]   CAN UK-14, 304-18 LOWER IOP IN RABBITS BY A PERIPHERAL MECHANISM [J].
BURKE, J ;
CROSSON, C ;
POTTER, D .
CURRENT EYE RESEARCH, 1989, 8 (06) :547-552
[3]  
DAVIS AA, 1990, INVEST OPHTH VIS SCI, V31, P2514
[4]   MONOCLONAL-ANTIBODIES FOR TREATING CANCER [J].
DILLMAN, RO .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (07) :592-603
[5]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
[6]  
FULCHER S, 1988, INVEST OPHTH VIS SCI, V29, P755
[7]   IMMUNORADIOACTIVE AGENT AGAINST CANCER [J].
GHOSE, T ;
CERINI, M ;
CARTER, M ;
NAIRN, RC .
BRITISH MEDICAL JOURNAL, 1967, 1 (5532) :90-&
[8]   LONG-TERM INHIBITION OF CELLULAR PROLIFERATION BY IMMUNOTOXINS [J].
HERMSEN, VM ;
FULCHER, SFA ;
SPIEKERMAN, AM ;
PHINIZY, JL ;
DITULLIO, NW .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (07) :1009-1011
[9]   NEW METHODS OF MEASURING RATE OF AQUEOUS FLOW IN MAN WITH FLUORESCEIN [J].
JONES, RF ;
MAURICE, DM .
EXPERIMENTAL EYE RESEARCH, 1966, 5 (03) :208-&
[10]   STUDIES IN UVEAL PHYSIOLOGY .2. CLINICAL STUDIES OF ANTERIOR CHAMBER CLEARANCE OF ISOTOPIC TRACERS [J].
OROURKE, J ;
MACRI, FJ .
ARCHIVES OF OPHTHALMOLOGY, 1970, 84 (04) :415-&